Preclinical pharmacology of BMS-275183, an orally active taxane

Clinical Cancer Research

Volumn 7, Issue 7, 2001, Pages 2016-2021

  Rose, W C ^a   Long, B H ^a   Fairchild, C R ^a   Lee, F Y F ^a   Kadow, J F ^a  

^a BRISTOL MYERS SQUIBB   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BMS 275183; PACLITAXEL; TAXANE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; COLON CARCINOMA; DRUG MECHANISM; HUMAN; HUMAN CELL; LUNG CANCER; MOUSE; NONHUMAN; OVARY TUMOR; PRIORITY JOURNAL; PROSTATE TUMOR; RAT; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; ANIMALS; ANTINEOPLASTIC AGENTS; BRIDGED COMPOUNDS; CELL SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; INHIBITORY CONCENTRATION 50; INJECTIONS, INTRAVENOUS; MALE; MICE; MICE, INBRED BALB C; MICE, INBRED C3H; MICE, INBRED DBA; MICE, NUDE; NEOPLASM TRANSPLANTATION; NEOPLASMS, EXPERIMENTAL; PACLITAXEL; RATS; RATS, NUDE; TIME FACTORS; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 0034778514     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Preclinical antitumor activity of taxanes
2. UFT/oral calcium folinate plus weekly paclitaxel for metastatic breast cancer
3. Paclitaxel efficacy and tolerability in second-line treatment of refractory and relapsed ovarian cancer patients
4. Paclitaxel activity, dose and schedule: Data from Phase III trials in metastatic breast cancer
5. One-hour paclitaxel infusions: Review of safety and efficacy
6. Single-agent paclitaxel in the treatment of breast cancer: Phase I and II development
7. Docetaxel (Taxotere) administered in weekly schedules
8. Weekly administration of docetaxel (Taxotere): Summary of clinical data
9. Weekly docetaxel in minimally pretreated cancer patients: A dose-escalation study focused on feasibility and cumulative toxicity of long-term administration
10. Weekly paclitaxel therapy: Current status and future directions in advanced ovarian cancer
11. Plasma pharmacokinetics and tissue distribution of paclitaxel in CD2F1 mice
12. Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine
13. Co-administration of cyclosporin enables oral therapy with paclitaxel
14. Preclinical oral antitumor activity of BMS-185660, a paclitaxel derivative
15. Experimental antitumor activity of Taxotere (RP 56976, NSC 628503), a Taxol analogue
16. Mechanisms of resistance to etoposide and teniposide in acquired resistant human colon and lung carcinoma cell lines
17. Paclitaxel-resistant human ovarian cancer cells have mutant Β-tubulins that exhibit impaired paclitaxel-driven polymerization
18. Preclinical antitumor activity of two novel taxanes
19. Comparison of MTT, XTT, and a novel tetrazolium compound MTS for in vitro proliferation and chemosensitivity assays
20. Preparation of tubulin from brain
21. Biologically active Taxol analogues with deleted A-ring side chain substituents and variable C-2′ configurations
22. Oral chemotherapeutic agents for colorectal cancer
23. Patient preferences for oral versus intravenous palliative chemotherapy
24. Paclitaxel: An inhibitor of angiogenesis in a vascularized breast cancer
25. High-time chemotherapy or high time for low dose